<DOC>
	<DOCNO>NCT01540500</DOCNO>
	<brief_summary>The purpose research study evaluate whether administration CYP1A2 inhibitor affect single-dose pharmacokinetics tasimelteon metabolite . The safety tolerability tasimelteon also assess throughout study .</brief_summary>
	<brief_title>Pharmacokinetics Tasimelteon Alone Combination With CYP1A2 Inhibitor , Fluvoxamine</brief_title>
	<detailed_description />
	<mesh_term>Fluvoxamine</mesh_term>
	<mesh_term>Cytochrome P-450 CYP1A2 Inhibitors</mesh_term>
	<criteria>1 . Men woman 18 55 year , inclusive ; 2 . Nonsmokers [ abstinence smoking least 6 month screen visit ] test negative cotinine screen baseline ; 3 . Subjects Body Mass Index ( BMI ) ≥18 ≤35 kg/m2 ( BMI = weight ( kg ) / [ height ( ) ] 2 ) ; 4 . Males , nonfecund female ( i.e. , surgically sterilize , procedure do 6 month screen subject postmenopausal , without menses 6 month screen ) , females childbearing potential use acceptable method birth control period 35 day first dose female must negative pregnancy test screen baseline visit ; 5 . Note 1 : Acceptable method birth control include one following : abstinence , vasectomize sexual partner , hormonal method ( i.e . pill , hormonal IUD , DepoProvera , implant , patch , intravaginal device [ NuvaRing ] ) , intrauterine device ( IUD [ copper band coil ] ) , diaphragm , cervical cap , condom spermicidal jelly foam . 6 . Vital sign ( 3 minute rest semisupine position ) within range show : Body temperature 35.037.5 °C ; Systolic blood pressure 90150 mmHg ; Diastolic blood pressure 5095 mmHg ; Pulse rate 50100 bpm . 7 . Ability acceptance provide write informed consent ; 8 . Willing able comply study requirement restriction ; 9 . Subjects must good health determine past medical history , physical examination , electrocardiogram , clinical laboratory test . 1 . History recent ( within six month ) drug alcohol abuse define DSM IV , Diagnostic Criteria Drug Alcohol Abuse evidence abuse indicate laboratory assay conduct Screening Visit Baseline ; 2 . Any major surgery within three month Baseline minor surgery within one month ; 3 . History current evidence cardiovascular , hepatic , hematopoietic , renal , gastrointestinal metabolic dysfunction judge Investigator clinically significant ; 4 . Subjects currently consider suicide risk , subject ever make suicide attempt , currently demonstrate active ( within last year ) suicidal ideation deem Columbia Suicide Severity Rating Scale ( CSSRS ) ; 5 . Any condition require regular use medication except listed Section 8.2 ; 6 . Exposure investigational drug , include placebo , within 30 day 5 halflives ( whichever longer ) baseline ; 7 . Anyone take melatonin preparation chronically within past two month prior Day 1 ; 8 . Donation loss 400 mL blood within two month prior Baseline Visit ; 9 . Significant illness within two week prior Baseline ; 10 . A known intolerance hypersensitivity fluvoxamine , tasimelteon drug similar tasimelteon ( include melatonin ) fluvoxamine ; 11 . Pregnant lactating female ; 12 . History liver disease and/or positive one follow serological result : A positive hepatitis C antibody test ( antiHCV ) A positive hepatitis B surface antigen ( HBsAg ) A positive HIV test result 13 . Exposure ( within 2 week Baseline Visit ) overthecounter medication include dietary supplement and/or herbal remedy , except list Section 8.2 ; 14 . Treatment drug know cause major organ system toxicity ( e.g. , chloramphenicol tamoxifen ) 60 day precede Screening visit ; 15 . Participation previous BMS214778/VEC162 trial ; 16 . Use food beverage contain grapefruit grapefruit juice , apple orange juice , vegetables mustard green family ( e.g . kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard green ) charbroiled meat least 2 week Baseline Visit end study ; 17 . Inability venipunctured and/or tolerate venous access ; 18 . Subjects unable read speak English ; 19 . Any sound medical reason determine clinical Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug Interaction</keyword>
</DOC>